Zoetis Inc.

NYSE:ZTS Rapport sur les actions

Capitalisation boursière : US$79.0b

Zoetis Croissance future

Future contrôle des critères 2/6

Zoetis devrait augmenter ses bénéfices et son chiffre d'affaires de 9.9% et de 5.8% par an respectivement. Le BPA devrait croître de de 10.6% par an. Le rendement des capitaux propres devrait être 45.9% dans 3 ans.

Informations clés

9.9%

Taux de croissance des bénéfices

10.6%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices23.8%
Taux de croissance des recettes5.8%
Rendement futur des capitaux propres45.9%
Couverture par les analystes

Good

Dernière mise à jour12 Nov 2024

Mises à jour récentes de la croissance future

The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 04
The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Recent updates

Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy

Nov 18

Zoetis (NYSE:ZTS) Has A Pretty Healthy Balance Sheet

Oct 26
Zoetis (NYSE:ZTS) Has A Pretty Healthy Balance Sheet

Zoetis: A Solid Choice For The Young Dividend Growth Investor

Oct 09

Do Zoetis' (NYSE:ZTS) Earnings Warrant Your Attention?

Oct 08
Do Zoetis' (NYSE:ZTS) Earnings Warrant Your Attention?

Zoetis: Investing In Pet Health And Portfolio Wealth

Sep 26

Are Investors Undervaluing Zoetis Inc. (NYSE:ZTS) By 23%?

Sep 20
Are Investors Undervaluing Zoetis Inc. (NYSE:ZTS) By 23%?

There's Reason For Concern Over Zoetis Inc.'s (NYSE:ZTS) Price

Aug 30
There's Reason For Concern Over Zoetis Inc.'s (NYSE:ZTS) Price

Zoetis: Librela Sales Should Peak 200-300% Above Management's $1B Target

Aug 13

Zoetis Q2 Earnings: Harvesting From DTC (Rating Upgrade)

Aug 07

Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?

Jul 16
Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?

Zoetis: A High-Quality Business And Fast Dividend Growth At A Reasonable Price

Jul 03

Zoetis: Don't Fret Excessively Over The Animal Healthcare Leader

Jun 11

A Look At The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Jun 10
A Look At The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Zoetis (NYSE:ZTS) Ticks All The Boxes When It Comes To Earnings Growth

May 23
Zoetis (NYSE:ZTS) Ticks All The Boxes When It Comes To Earnings Growth

Zoetis: Why The Focus On Companion Animal Segment Will Pay Off

May 22

The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 04
The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Zoetis: Long-Term Buy Despite Safety Concerns

May 03

Despite Lawsuit Risks: Why Zoetis Remains A Compelling Investment

Apr 15

Zoetis Inc.'s (NYSE:ZTS) Shareholders Might Be Looking For Exit

Apr 12
Zoetis Inc.'s (NYSE:ZTS) Shareholders Might Be Looking For Exit

Zoetis: My Favorite Healthcare Stock Right Now

Mar 21

Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)

Mar 03
Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)

Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness

Feb 27

Animal Kingdom's Ally: Zoetis And Its Path To 10%+ Returns

Jan 10

Some Confidence Is Lacking In Zoetis Inc.'s (NYSE:ZTS) P/E

Jan 01
Some Confidence Is Lacking In Zoetis Inc.'s (NYSE:ZTS) P/E

Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Dec 14
Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?

Dec 06
Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?

Here's Why We Think Zoetis (NYSE:ZTS) Might Deserve Your Attention Today

Nov 18
Here's Why We Think Zoetis (NYSE:ZTS) Might Deserve Your Attention Today

Zoetis: High-Quality Compounder With A Reasonable Price After Earnings

Nov 09

Zoetis: Significant CapEx Investments For Long-Term Growth, But A Hold Now

Oct 26

Zoetis Is An Impressive Healthcare Compounder

Sep 26

Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Sep 25
Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Here's Why Zoetis (NYSE:ZTS) Can Manage Its Debt Responsibly

Sep 04
Here's Why Zoetis (NYSE:ZTS) Can Manage Its Debt Responsibly

Zoetis: Pawses Pain, Librela OA Treatment Targets Furry Friends In The U.S.

Aug 22

Should You Be Adding Zoetis (NYSE:ZTS) To Your Watchlist Today?

Aug 12
Should You Be Adding Zoetis (NYSE:ZTS) To Your Watchlist Today?

Zoetis: My Dog Approves Of This Dividend Compounder

Jul 19

Zoetis: A Purrfect Addition To Your Portfolio

Jun 22

Does This Valuation Of Zoetis Inc. (NYSE:ZTS) Imply Investors Are Overpaying?

Jun 10
Does This Valuation Of Zoetis Inc. (NYSE:ZTS) Imply Investors Are Overpaying?

These 4 Measures Indicate That Zoetis (NYSE:ZTS) Is Using Debt Reasonably Well

Apr 16
These 4 Measures Indicate That Zoetis (NYSE:ZTS) Is Using Debt Reasonably Well

Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Mar 10
Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Zoetis rises on 2023 revenue forecast above estimates, Q4 profit in-line with consensus

Feb 14

Prévisions de croissance des bénéfices et des revenus

NYSE:ZTS - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/202610,3863,0342,9573,42014
12/31/20259,7282,7192,6303,16515
12/31/20249,2622,4612,2192,71212
9/30/20249,1522,4302,3082,945N/A
6/30/20248,9152,3442,1032,718N/A
3/31/20248,7342,3911,7502,399N/A
12/31/20238,5442,3441,6212,353N/A
9/30/20238,3712,2801,4922,197N/A
6/30/20238,2222,2131,2851,999N/A
3/31/20238,0942,0711,4582,152N/A
12/31/20228,0802,1141,3261,912N/A
9/30/20228,0072,0671,2671,850N/A
6/30/20227,9952,0901,4291,977N/A
3/31/20227,8912,0731,6072,122N/A
12/31/20217,7762,0371,7362,213N/A
9/30/20217,6161,9821,7912,252N/A
6/30/20217,4121,9091,7022,161N/A
3/31/20217,0121,7741,6822,118N/A
12/31/20206,6751,6381,6732,126N/A
9/30/20206,5421,6631,5231,990N/A
6/30/20206,3401,6171,4561,934N/A
3/31/20206,3391,6111,3231,814N/A
12/31/20196,2601,5001,3351,795N/A
9/30/20196,1501,4611,3651,797N/A
6/30/20196,0461,3751,4631,841N/A
3/31/20195,9141,3881,4421,790N/A
12/31/20185,8251,4281,4521,790N/A
9/30/20185,7211,1641,5311,814N/A
6/30/20185,5881,115N/A1,703N/A
3/31/20185,442978N/A1,616N/A
12/31/20175,307864N/A1,346N/A
10/1/20175,124937N/A1,024N/A
7/2/20175,018878N/A824N/A
4/2/20174,957855N/A781N/A
12/31/20164,888821N/A713N/A
10/2/20164,885689N/A705N/A
7/3/20164,858639N/A670N/A
4/3/20164,825378N/A655N/A
12/31/20154,765339N/A664N/A
9/27/20154,811443N/A773N/A
6/28/20154,807420N/A672N/A
3/29/20154,790593N/A709N/A
12/31/20144,785583N/A626N/A
9/28/20144,719562N/A537N/A
6/29/20144,612527N/A548N/A
3/30/20144,568519N/A377N/A
12/31/20134,561504N/A681N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de ZTS ( 9.9% par an) est supérieure au taux d'épargne ( 2.6% ).

Bénéfices vs marché: Les bénéfices de ZTS ( 9.9% par an) devraient croître plus lentement que le marché US ( 15.3% par an).

Croissance élevée des bénéfices: Les bénéfices de ZTS devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de ZTS ( 5.8% par an) devrait croître plus lentement que le marché de US ( 8.9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de ZTS ( 5.8% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de ZTS devrait être très élevé dans 3 ans ( 45.9 %).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y